Nutrition in Gilbert's Syndrome-A Systematic Review of Clinical Trials According to the PRISMA Statement.
Zuzanna Sabina GoluchAldona Wierzbicka-RucińskaEwelina Ewa KsiążekPublished in: Nutrients (2024)
Gilbert syndrome is the most common hyperbilirubinemia, associated with a mutation in the UGT1A1 bilirubin gene, which produces an enzyme that conjugates bilirubin with glucuronic acid. Episodes of jaundice occurring in GS negatively affect patients' quality of life. This systematic review aimed to analyze clinical studies regarding nutrition in people with GS. The study followed the PRISMA guidelines and utilized the Ebsco, Embase, Cochrane, PubMed, Scopus, and Web of Science databases to search clinical trials focused on diet/nutrition in GS (1963-2023 years). The methodological quality of selected studies was assessed using the Jadad scale. As a result, 19 studies met the inclusion criteria. The research mainly focused on the impact of caloric restriction, consumption of various diet variants, and vegetables and fruits on hyperbilirubinemia and metabolic health. A nutritional intervention consisting of not applying excessive calorie restrictions and consuming fats and biologically active compounds in vegetables and fruits ( Cruciferae , Apiaceous , Rutaceae ) may prevent the occurrence of jaundice episodes. It is justified to conduct further research on detecting such compounds in food, which, by influencing the expression of the UGT liver enzyme gene, could contribute to regulating bilirubin concentration in the blood of people with GS.
Keyphrases
- physical activity
- clinical trial
- systematic review
- meta analyses
- copy number
- weight loss
- public health
- human health
- end stage renal disease
- risk assessment
- randomized controlled trial
- poor prognosis
- genome wide
- ejection fraction
- newly diagnosed
- chronic kidney disease
- case control
- mental health
- case report
- body mass index
- weight gain
- health risk assessment
- prognostic factors
- genome wide identification
- dna methylation
- heavy metals
- gene expression
- phase ii
- climate change
- transcription factor
- drug delivery
- big data
- health information
- phase iii
- cancer therapy
- open label
- tyrosine kinase
- binding protein
- deep learning
- double blind
- patient reported
- quality improvement
- health promotion
- social media